RIBOPRO is a Noord-Brabant–based biotechnology company developing proprietary mRNA technologies and high-quality mRNA/LNP manufacturing for biotech and biopharma customers. The company is focused on next-generation lipid nanoparticle (LNP) technology and a state-of-the-art mRNA/LNP manufacturing machine. It serves hundreds of existing customers and aims to accelerate acquisition of new partnerships through improved mRNA/LNP performance. RIBOPRO will use the new capital to advance several R&D initiatives to specific value inflection points and to streamline production processes. Management intends to deliver proof of concept for its LNP technology and to become a go-to provider of mRNA technologies and GMP manufacturing. Financially, RIBOPRO secured a €1.9M Convertible Loan Agreement to support its R&D and manufacturing development as it seeks to grow into a mature and profitable company. RiboPro develops high-performance custom messenger RNA products used as research tools and in therapeutics and vaccines. The company sells R&D and production services to academic, biotech and pharma researchers to accelerate science and drug and vaccine development. RiboPro plans to use new funding to advance its proprietary mRNA technology, strengthen the team and scale the business. Management positions the products as increasing mRNA activity while decreasing toxicity and immunogenic response, with applications in research, tissue engineering and therapeutics. The company presents itself as aiming to become a global provider of top-quality mRNA and to accelerate adoption of mRNA in medicines and vaccines. Founders include Sander van Asbeck (CEO), Dr. Jürgen Dieker (CSO) and Dr. Roland Brock.

Total raised

$3M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Jan 2024